The lung cancers: staging and response, CT, 18F-FDG PET/CT, MRI, DWI: review and new perspectives
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer
deaths in both sexes combined. Recent years have seen major advances in the diagnostic …
deaths in both sexes combined. Recent years have seen major advances in the diagnostic …
Imaging in Lung Cancer Staging
CD Strange, TA Strange, LT Erasmus… - Clinics in Chest …, 2024 - chestmed.theclinics.com
Despite improvements in diagnosis and treatment, lung cancer remains one of the leading
causes of death in the United States and worldwide. It is estimated that in the United States …
causes of death in the United States and worldwide. It is estimated that in the United States …
[HTML][HTML] Neoadjuvant immune-checkpoint inhibitors in lung cancer-a primer for radiologists
D Kifjak, MJ Hochmair, D Krenbek, RI Milos… - European Journal of …, 2023 - Elsevier
The introduction of neoadjuvant immune checkpoint inhibitors plus platinum-based
chemotherapy has changed treatment regimens of patient's early-stage lung cancer. This …
chemotherapy has changed treatment regimens of patient's early-stage lung cancer. This …
[PDF][PDF] 18F-FDGPET/CT 在非小细胞肺癌预后评估中的研究进展
黄丹琪， 刘珈， 李国栋， 刘彩云， 王博平… - 滨州医学院 …, 2024 - manu58.magtech.com.cn
肺癌是一种进展迅速的疾病, 预后不良. 准确的治疗前分期和预后评估可改善非小细胞肺癌(
NSCLC) 的诊疗管理. 18F FDGPET/CT 可从分子水平准确地反映肿瘤的生物学特性 …
NSCLC) 的诊疗管理. 18F FDGPET/CT 可从分子水平准确地反映肿瘤的生物学特性 …
Staging Workup and Staging System for Lung Cancer
G Ak, CF Thomas - Airway diseases, 2023 - Springer
Lung cancer is the leading cause of cancer deaths worldwide. Staging is an essential step in
managing patients with lung cancer for treatment selection and prognosis. The TNM staging …
managing patients with lung cancer for treatment selection and prognosis. The TNM staging …
Authors' reply to Krishnamurthy et al.
Cancer Research, Statistics, and Treatment/Volume 5/Issue 4/October-December 2022
nodes occurs in< 1% of patients with non‑small‑cell lung cancer at presentation, and in …
nodes occurs in< 1% of patients with non‑small‑cell lung cancer at presentation, and in …